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AbstrAct
Objective To describe the efficacy of tofacitinib in 
reducing pain in patients with rheumatoid arthritis (ra), 
psoriatic arthritis (Psa) or ankylosing spondylitis (as) in a 
post- hoc analysis of randomised controlled trials.
Methods Data were collected from patients in seven 
tofacitinib studies: six phase iii (four ra, two Psa) and 
one phase ii study (as), and grouped into five analysis 
populations based on rheumatic disease diagnosis and 
category of prior inadequate response (ir) to treatment: 
conventional synthetic disease- modifying antirheumatic 
drugs- ir (ra and Psa), tumour necrosis factor inhibitors- ir 
(ra and Psa), or non- steroidal anti- inflammatory drugs- ir 
(as). Only patients who received tofacitinib 5 or 10 mg 
twice daily or placebo were included. Pain assessments 
included: Patient’s assessment of arthritis Pain, short- 
Form health survey 36v2 Question (Q)7 and Bodily Pain 
domain, ankylosing spondylitis Quality of life Q9 and Q14, 
euroQol Five Dimensions Pain/Discomfort dimension and 
Bath ankylosing spondylitis Disease activity index Q2 and 
Q3. Data were reported to month 6 (placebo to month 3) in 
the ra and Psa populations, and week 12 (tofacitinib and 
placebo) in the as population.
Results Overall, 3330 patients were included in 
this analysis. in the ra and Psa populations, pain 
improvements in tofacitinib- treated patients compared 
with placebo were observed at the earliest time point 
assessed and at month 3 (maintained to month 6). in the 
as population, pain improvements compared with placebo 
were observed at week 12.
Conclusion Tofacitinib was associated with rapid and 
sustained improvements across multiple pain measures 
in patients with inflammatory rheumatic musculoskeletal 
diseases.
InTROduCTIOn
Pain is the most common and most impactful 
patient- reported symptom in inflamma-
tory rheumatic musculoskeletal diseases 
(RMDs).1 2 In a survey of 1204 patients with 
rheumatoid arthritis (RA), 68.6% reported 
pain as the most important area required 
for health improvement.2 The importance 
of pain in psoriatic arthritis (PsA) is demon-
strated by its inclusion in a core domain set 
of disease features that should be measured 
in all clinical trials related to the treatment 
of patients with PsA.3 Similarly, in ankylosing 
spondylitis (AS), pain is included as part of 
a core set for monitoring patients with AS 
in clinical practice.4 Therapies that alleviate 
Key messages
What is already known about this subject?
 ► Pain is the most common and impactful patient- 
reported symptom in inflammatory rheu-
matic musculoskeletal disease (rMD) and is 
considered important by both patients and health-
care professionals.
 ► Tofacitinib is approved for the treatment of rheu-
matoid arthritis (ra), psoriatic arthritis (Psa) and 
moderate- to- severe ulcerative colitis, and is in de-
velopment for the treatment of ankylosing spondy-
litis (as).
What does this study add?
 ► across ra, Psa and as, tofacitinib was associated 
with rapid or early alleviation of pain, and sustained 
improvements, assessed using both unidimensional 
pain measures and individual pain components of 
multidimensional measures.
 ► improvements appeared consistent, irrespective 
of tofacitinib dose or prior inadequate response to 
conventional synthetic disease- modifying antirheu-
matic drug, tumour necrosis factor inhibitor (ra or 
Psa) or non- steroidal anti-inflammatory drug (as) 
treatment.
How might this impact on clinical practice or 
future developments?
 ► Tofacitinib was associated with rapid and sustained 
improvements across multiple pain measures in pa-
tients with inflammatory rMDs.
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pain in inflammatory RMDs are therefore considered to 
be of high importance by patients and healthcare profes-
sionals.3
Traditionally, the pain experienced from RMDs was 
primarily attributed to peripheral nociceptive aetiolo-
gies (eg, inflammation or structural damage).5 However, 
patient reports of persistence of pain despite regression 
of inflammatory markers have highlighted the role of 
neurogenic mechanisms as significant factors in RMD- 
associated chronic pain.5–7 Chronic pain is a critical 
symptom of RMD progression, involving a multifaceted 
pathophysiological phenomenon including the release 
of various inflammatory factors, and peripheral and 
central pain- processing mechanisms (sensitisation).6 In 
recent years, the Janus kinase and signal transducer and 
activator of transcription (JAK- STAT) signalling pathway 
has been recognised as a key player in feedback loops 
involving pronociceptive and anti- inflammatory cyto-
kines.8 Proinflammatory molecules may in turn sensitise 
neurons to pain signals. For example, patients with RA 
demonstrate enhanced sensitivity to nociceptive stimuli, 
and studies in rat models suggest that JAK/STAT signal-
ling can promote mechanical pain sensitivity. Further-
more, studies in mice suggest that non- inflammatory 
molecules, such as the nociceptive chemokine CXCL1, 
may promote pain by activating sensory neurons.
Pain intensity and pain alleviation are important 
constructs that may be usefully evaluated in clinical 
trials.9 Patient- reported pain is typically measured using 
unidimensional questionnaires or single questions incor-
porated into a multidimensional assessment.10 Unidi-
mensional measures may assess pain through a Visual 
Analogue Scale (VAS; from 0 mm (‘no pain’) to 100 mm 
(‘worst imaginable pain’)), or a Numeric Rating Scale for 
Pain (0 (‘no pain’) to 10 (‘worst imaginable pain’)). Such 
assessments are not specific to RMDs and can also be used 
in other patient populations. Generic multidimensional 
assessments applicable to various therapeutic areas and 
the general population (eg, Short- Form Health Survey 
36v2 (SF- 36v2) 11 and the EuroQol Five Dimensions ques-
tionnaire (EQ- 5D)12 13), as well as those specific to RMDs 
(eg, American College of Rheumatology improvement 
criteria,14 Bath Ankylosing Spondylitis Disease Activity 
Index (BASDAI)15 and the Ankylosing Spondylitis Quality 
of Life (ASQoL) questionnaire16) also include pain as a 
key assessment within their frameworks.
Pain has been assessed in a large number of RA, PsA and 
AS randomised controlled trials (RCTs). In patients with 
RA, a network meta- analysis of 17 RCTs concluded that 
there was strong evidence that current biologic disease- 
modifying antirheumatic drug (bDMARD) interventions 
improve patient- reported pain, compared with placebo.17 
This was also observed in studies in patients with PsA18–20 
and a systematic review of studies in patients with AS,21 
which reported that tumour necrosis factor inhibitors 
(TNFi) improved the symptoms of pain, compared with 
placebo.
Tofacitinib is an oral JAK inhibitor for the treatment of 
RA and PsA, and is under investigation for the treatment 
of AS. The efficacy of tofacitinib in improving patient- 
reported outcomes (PROs), including pain, has been 
demonstrated in PRO components of phase III RCTs in 
patients with RA22–26 and PsA,27 28 and in a phase II RCT 
in patients with AS.29
Pain reduction in patients treated with tofacitinib may 
be linked to the previously observed effect of tofacitinib 
on inflammation. For example, a statistically significant 
reduction in spinal inflammation has been reported in 
patients with AS receiving tofacitinib 5 mg and 10 mg 
twice daily (BID), compared with placebo.29 Further-
more, studies have reported that tofacitinib downreg-
ulates proinflammatory pathways in both RA and PsA 
models.30 31 Additionally, the suggestion that JAK/STAT 
signalling can promote mechanical pain sensitivity 
alludes to a possible link between tofacitinib and pain 
reduction,32 in addition to its proposed role in reducing 
inflammation.31
The objective of this post- hoc analysis was to use unidi-
mensional pain measures and pain- specific compo-
nents within multidimensional assessments to evaluate 
the efficacy of tofacitinib in reducing pain across three 
inflammatory RMDs (RA, PsA and AS) and subdivided 
according to inadequate response to previous therapies.
PaTIenTs and MeTHOds
Patients and study designs
This post- hoc analysis used data from the following 
double- blind, placebo- controlled RCTs, which all evalu-
ated the impact of tofacitinib on patient- reported pain: 
four phase III RCTs in patients with RA (ORAL Scan 
(NCT00847613), ORAL Sync (NCT00856544), ORAL 
Standard (NCT00853385), ORAL Step (NCT00960440)); 
two phase III RCTs in patients with PsA (OPAL Broaden 
(NCT01877668), OPAL Beyond (NCT01882439)); 
and one phase II RCT in patients with AS (A3921119 
(NCT01786668)).
The details of the individual trial designs and patient 
populations have been previously reported.29 33–38 In all 
studies, patients were aged ≥18 years and had a diagnosis 
of active disease at screening. Patients in the RA and 
PsA studies were required to be receiving concomitant 
conventional synthetic disease- modifying antirheumatic 
drug (csDMARD) treatment. Patients in the AS study 
were permitted to be receiving a stable dose of metho-
trexate (MTX) or sulfasalazine.
Patients with RA met the American College of Rheu-
matology 1987 Revised Criteria,33–35 39 and patients with 
PsA were classified based on fulfilment of ClASsification 
criteria for Psoriatic ARthritis.37 38 40 Studies were of 6–24 
months’ duration in RA, and 6 or 12 months' duration 
in PsA, with patients in all studies randomised to receive 
tofacitinib 5 mg BID, tofacitinib 10 mg BID or placebo. 
In PsA studies (OPAL Broaden and OPAL Beyond) 
and ORAL Step (RA), patients treated with placebo 
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Table 1 Patient populations and studies
Patients included in analysis, N (FAS)
Tofacitinib 5 mg 
BID
Tofacitinib 10 mg 
BID Placebo Total
RA csDMARD- IR analysis population
ORAL Scan (A3921044; NCT00847613)35
A 24- month phase III study in MTX- IR patients with active RA receiving background 
MTX (tofacitinib 5 or 10 mg BID or placebo; n=797)
826 821 419 2066
ORAL Sync (A3921046; NCT00856544)34
A 12- month phase III study in patients with active RA and inadequate response to 
≥1 csDMARD or bDMARD who were receiving background csDMARDs (tofacitinib 5 
or 10 mg BID or placebo; n=792)
ORAL Standard* (A3921064; NCT00853385)36
A 12- month phase III study in MTX- IR patients with active RA receiving background 
MTX (tofacitinib 5 or 10 mg BID, adalimumab 40 mg Q2W or placebo; n=717)
RA TNFi- IR analysis population
ORAL Step (A3921032; NCT00960440)33
A 6- month phase III study in TNFi- IR patients with active RA receiving background 
MTX (tofacitinib 5 or 10 mg BID or placebo; n=399)
133 134 132 399
PsA csDMARD- IR analysis population
OPAL Broaden (A3921091; NCT01877668)38
A 12- month phase III study in TNFi- naïve csDMARD- IR patients with active PsA 
receiving a background csDMARD (tofacitinib 5 or 10 mg BID, adalimumab 40 mg 
Q2W or placebo; n=442)
107 104 105 316
PsA TNFi- IR analysis population
OPAL Beyond (A3921125; NCT01882439)37
A 6- month phase III study in TNFi- IR patients with active PsA receiving a 
background csDMARD (tofacitinib 5 or 10 mg BID or placebo; n=395)
131 132 131 394
AS NSAID- IR analysis population
A3921119 (NCT01786668)29
A 16- week (12- week treatment, 4- week washout) phase II study in patients with 
active AS and inadequate response to ≥2 NSAIDs or intolerance to prior NSAIDs 
(tofacitinib 2, 5 or 10 mg BID or placebo; n=208)
52 52 51 155
*After the publication of ORAL Standard, one study site (nine patients randomised) was found to be non- compliant to study procedures, and those 
patients were removed from efficacy analyses.
AS, ankylosing spondylitis; bDMARD, biologic DMARD; BID, twice daily; csDMARD, conventional synthetic DMARD; DMARD, disease- modifying 
antirheumatic drug; FAS, full analysis set; IR, inadequate response; MTX, methotrexate; NSAID, non- steroidal anti- inflammatory drug; PsA, psoriatic 
arthritis; Q2W, once every 2 weeks; RA, rheumatoid arthritis; TNFi, tumour necrosis factor inhibitor.
were blindly switched to tofacitinib at month 3, or were 
blindly switched at month 3 if an insufficient therapeutic 
response was experienced. In ORAL Scan, ORAL Sync 
and ORAL Standard (RA), patients were blindly switched 
at month 6. In the ORAL Standard (RA) and OPAL 
Broaden (PsA) studies, patients were also randomised to 
an active control arm of adalimumab 40 mg once every 2 
weeks (not included in this analysis).
Patients with AS fulfilled the modified New York 
criteria for AS (confirmed by centralised reading of 
sacroiliac radiographs),29 and had active disease based 
on a BASDAI score ≥4 and a back pain score (BASDAI 
Question (Q)2)≥4. All patients were randomised to 
receive tofacitinib 2 mg BID, tofacitinib 5 mg BID, tofac-
itinib 10 mg BID or placebo, which was maintained for 
the 12- week duration of the study. Patients randomised 
to tofacitinib 2 mg BID were not reported in this analysis 
so results could be compared with patients in the RA or 
PsA studies.
Patients from the seven RCTs were grouped into five 
analysis populations according to their rheumatic inflam-
matory disease (RA, PsA or AS) and inadequate response 
to previous therapies: patients with RA and inadequate 
response to csDMARDs (csDMARD- IR; pooled from 
three studies); patients with PsA and csDMARD- IR (one 
study); patients with RA and inadequate response to TNFi 
(TNFi- IR; one study); patients with PsA and TNFi- IR (one 
study); and patients with AS and an inadequate response 
to non- steroidal anti- inflammatory drugs (NSAID- IR; one 
study) (table 1).
Pain assessments
Patient- reported pain was assessed using the following 
measures:
Patient’s Assessment of Arthritis Pain (PAAP) score 
(VAS 0–100 mm; higher scores indicated worse arthritis 
pain)41 was assessed in all RA and PsA populations at 
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baseline, and months 1, 3 and 6. PAAP was also assessed 
at week 2 (ORAL Sync and ORAL Step (RA), and in both 
PsA populations), month 2 (ORAL Sync (RA), and in 
both PsA populations) month 4 (PsA populations), and 
month 4.5 (ORAL Sync and ORAL Step (RA)).
Patients achieving a decrease in PAAP score from base-
line of ≥20 mm were assessed in all RA and PsA popu-
lations at months 1, 3 and 6. This was also assessed at 
week 2 (ORAL Sync and ORAL Step (RA), and in both 
PsA populations), month 2 (ORAL Sync (RA), and in 
both PsA populations), month 4 (PsA populations) and 
month 4.5 (ORAL Sync and ORAL Step (RA)).
SF- 36v2 Q7: ‘How much bodily pain have you had 
during the past week?’ (range, 1–6 with 1=none, 6=very 
severe) and SF- 36v2 Bodily Pain (BP) domain (norm- 
based score (theoretical range, 19.23–60.88),42 with 
higher scores indicating less pain) were assessed in RA 
populations at baseline, week 2 (ORAL Step only), and 
months 1, 3 and 6; in PsA populations at baseline and 
months 1, 3 and 6; and in the AS population at baseline 
and week 12.
EQ- 5D Pain/Discomfort (PD) (range 1–3, with 1=no 
pain or discomfort, 3=extreme pain or discomfort)12 
was assessed in RA and PsA populations at baseline, and 
months 1 (except ORAL Scan and ORAL Sync (RA)), 3, 
and 6, and in the AS population at baseline and week 12.
BASDAI Q2, assessing neck, back and hip pain (‘How 
would you describe the overall level of AS neck, back, or 
hip pain you have had?’) and Q3, assessing peripheral 
pain/swelling (‘How would you describe the overall level 
of pain/swelling in joints other than neck, back, hips you 
have had?’; VAS 0–10 cm in AS and VAS 0–100 mm in 
PsA; higher scores indicated worse pain), were assessed 
in the PsA populations at baseline and months 1, 3 and 
6, and the AS population at baseline and weeks 2, 4, 8 
and 12. In the PsA populations, BASDAI Q2 and Q3 were 
assessed only in patients who had spondylitis, as deter-
mined by the site investigator at screening, and baseline 
BASDAI total score >0.
Patients with a ‘yes’ response to ASQoL questionnaire 
Q9 (‘I have unbearable pain’) and Q14 (‘The pain is 
always there’) were assessed in the AS population at base-
line and week 12.
data analysis
Analyses were based on patients who received tofacitinib 
(5 mg or 10 mg BID) or placebo in one of the seven RCTs 
and had been included in the full analysis set (patients 
who were randomised and received ≥1 dose of study 
treatment).
Continuous endpoints (SF- 36v2 Q7 and BASDAI Q2 
and Q3) were summarised descriptively over time by 
mean and SE. Binary endpoints (PAAP response ≥20 
mm, patients answering ‘yes’ to ASQoL Q9 and Q14) 
were summarised descriptively over time by number 
and percentage of patients (SE). For the RA and PsA 
populations, data from patients receiving tofacitinib 
were summarised up to 6 months, with placebo data 
summarised up to 3 months (last time point before 
placebo- treated patients switched to tofacitinib in some 
studies); for the AS population, all data were summarised 
up to 12 weeks.
In addition, for the RA and PsA populations, least 
squares (LS) mean changes from baseline for PAAP, 
SF- 36v2 BP domain and EQ- 5D PD dimension were anal-
ysed using a repeated- measures model with fixed effects 
for treatment group, visit, interaction of the treatment 
group by visit, geographic location, study (if more than 
one) and baseline value. The model used a common 
unstructured variance–covariance matrix, without impu-
tation for missing data. Within this, two models were 
used: (1) up to month 3, the two placebo- to- tofacitinib 
sequences were combined into a single placebo group 
(pooled placebo group); (2) after month 3 (including 
all post- baseline data up to month 6), the placebo- to- 
tofacitinib sequences were kept separate. For the AS 
population, treatment comparisons between tofacitinib 
(5 mg or 10 mg BID) and placebo at week 12 were made 
using an analysis of covariance model, with fixed effects 
for treatment and baseline value; missing values were 
imputed by last observation carried forward.
Proportions of patients achieving a ≥20 mm decrease 
in PAAP score from baseline to month 3 were compared 
between tofacitinib (5 mg or 10 mg BID) and placebo, 
using large sample approximation of the difference 
in binomial proportions. When two or more studies 
were included, the Cochran- Mantel- Haenszel approach 
adjusting for study was used.
The cumulative distribution function plot for patients 
achieving specific changes from baseline in PAAP score 
was provided at month 3 in RA and PsA populations.43
P values were unadjusted.
ResulTs
Patients
In total, 3330 patients were included in this post- hoc anal-
ysis. In each of the seven RCTs, baseline demographics/
characteristics have been reported previously,29 33–36 44 45 
and were generally similar in the tofacitinib and placebo 
treatment arms. Between the RCTs, patients in the RA 
population were generally older (mean age, 50.8–55.5 
years) than those in the PsA (mean age, 46.9–51.3 years) 
and AS (mean age, 41.2–41.9 years) populations, with a 
longer average time since diagnosis (RA, 6.9–13.0 years; 
PsA, 5.3–9.6 years; AS, 1.5–4.1 years). Most of the RA 
population was female (80.2%–91.1%), compared with 
PsA, in which there were approximately equal propor-
tions of male and female patients (47%–61% female), 
and the AS population, which was predominantly male 
(25.0%–37.3% female). In the RA and PsA analysis popu-
lations, csDMARDs were required for inclusion, with 
most patients receiving MTX. In the AS population, most 
patients (88.5%–94.1%) were receiving concomitant 
NSAIDs.
copyright.
 o
n
 February 24, 2020 at University of G
lasgow. Protected by
http://rm
dopen.bmj.com/
R
M
D
 O
pen: first published as 10.1136/rm
dopen-2019-001042 on 3 February 2020. Downloaded from
 
5Ogdie a, et al. RMD Open 2020;6:e001042. doi:10.1136/rmdopen-2019-001042
Pain
Figure 1 LS mean (SE) change from baseline in PAAP (measured using a VAS (0–100 mm; higher score=worse arthritis 
pain)) scores in (A) RA csDMARD- IR, (B) RA TNFi- IR, (C) PsA csDMARD- IR and (D) PsA TNFi- IR analysis populations (FAS). 
Significance is given as unadjusted p values, compared with placebo: *p≤0.05, **p<0.01, ***p<0.001. LS mean changes from 
baseline in PAAP were analysed using a repeated- measures model with fixed effects for treatment group, visit, interaction 
of the treatment group by visit, geographic location, study (if more than one) and baseline value. The model used a common 
unstructured variance–covariance matrix, without explicit imputation for missing data. Within this, two models were used: (1) 
up to month 3, the two placebo- to- tofacitinib sequences were combined into a single placebo group (pooled placebo group); 
(2) after month 3 (including all post- baseline data up to month 6), the placebo- to- tofacitinib sequences were kept separate. 
BID, twice daily; csDMARD, conventional synthetic disease- modifying antirheumatic drug; FAS, full analysis set; IR, inadequate 
response; LS, least squares; PAAP, Patient’s Assessment of Arthritis Pain; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SE, 
standard error; TNFi, tumour necrosis factor inhibitor; VAS, visual analogue scale.
Between the TNFi- IR and csDMARD- IR populations in 
RA and PsA, baseline values for PAAP, SF- 36v2 BP domain 
and EQ- 5D PD dimension were generally similar.
Patient’s assessment of arthritis Pain
In the RA and PsA csDMARD- IR and TNFi- IR popu-
lations, significant improvements (reductions) in 
LS mean change from baseline in PAAP scores were 
reported as early as week 2 in the tofacitinib 5 and 
10 mg BID treatment groups compared with placebo 
(figure 1). This significant improvement persisted 
for both tofacitinib treatment groups compared with 
placebo at month 3 (p<0.001; figure 1, table 2; pain 
scores for individual RA studies22 24 26 46 and for PsA 
have been reported previously27 28). The improvements 
from baseline in PAAP scores in the tofacitinib treat-
ment arms were broadly maintained through month 6 
(figure 1).
In the same populations, the cumulative distribution 
function plots of patients achieving any level of decrease 
from baseline at month 3 in PAAP score were similar for 
patients receiving tofacitinib 5 mg or 10 mg BID, and 
greater than for patients treated with placebo (online 
supplementary figure 1). The proportions of tofacitinib- 
treated patients reporting a ≥20 mm improvement from 
baseline in PAAP scores at month 3 were significant across 
all these analysis populations compared with placebo 
(p<0.01; table 3). The proportion of tofacitinib- treated 
patients reporting improvements from baseline of ≥20 
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Table 2 LS mean (SE) change from baseline in PAAP, SF- 36v2 BP domain, and EQ- 5D PD dimension to month 3*
Analysis population
Baseline mean (SE) (N) Month 3* LS mean change from baseline (SE) (N)
Tofacitinib
5 mg BID
Tofacitinib
10 mg BID Placebo
Tofacitinib
5 mg BID
Tofacitinib
10 mg BID Placebo
PAAP¶             
  RA csDMARD- IR 58.09 (0.80)
(825)
58.28 (0.80)
(821)
55.78 (1.12)
(418)
−24.90 (0.88)
(773)***
−27.96 (0.88)
(775)***
−10.50 (1.17)
(390)
  RA TNFi- IR 65.73 (2.02)
(127)
60.10 (2.05)
(128)
60.74 (2.05)
(131)
−27.16 (2.43)
(114)***
−24.95 (2.48)
(119)***
−8.26 (2.41)
(115)
  PsA csDMARD- IR† 55.74 (2.21)
(107)
54.42 (2.12)
(104)
53.15 (2.29)
(105)
−21.49 (2.33)
(103)***
−27.10 (2.34)
(103)***
−10.22 (2.50)
(102)
  PsA TNFi- IR† 56.35 (2.12)
(130)
59.45 (1.94)
(132)
54.91 (2.21)
(131)
−21.66 (2.16)
(124)***
−20.88 (2.19)
(119)***
−7.72 (2.18)
(117)
SF- 36v2 BP domain‡
  RA csDMARD- IR 33.64 (0.26)
(825)
34.05 (0.26)
(821)
34.81 (0.37)
(418)
7.24 (0.32)
(772)***
9.26 (0.32)
(775)***
3.26 (0.43)
(389)
  RA TNFi- IR 31.09 (0.70)
(133)
32.55 (0.64)
(134)
31.95 (0.67)
(132)
8.05 (0.77)
(118)***
8.77 (0.78)
(125)***
2.49 (0.78)
(117)
  PsA csDMARD- IR† 34.62 (0.72)
(107)
34.91 (0.82)
(104)
35.10 (0.71)
(105)
5.51 (0.73)
(102)**
5.69 (0.74)
(103)**
2.68 (0.79)
(102)
  PsA TNFi- IR† 33.24 (0.69)
(130)
32.63 (0.60)
(132)
35.42 (0.76)
(131)
5.18 (0.68)
(121)***
5.34 (0.69)
(120)***
1.77 (0.69)
(117)
  AS NSAID- IR 33.26 (1.10)
(52)
32.46 (0.91)
(52)
34.40 (1.07)
(51)
10.03 (1.24)
(52)***
8.81 (1.28)
(52)**
3.57 (1.27)
(51)
EQ- 5D PD dimension§
  RA csDMARD- IR 2.22 (0.02)
(824)
2.19 (0.02)
(821)
2.16 (0.02)
(415)
−0.27 (0.02)
(740)***
−0.36 (0.02)
(736)***
−0.13 (0.03)
(367)
  RA TNFi- IR 2.39 (0.05)
(131)
2.26 (0.04)
(134)
2.35 (0.04)
(129)
−0.33 (0.05)
(115)**
−0.38 (0.05)
(124)***
−0.15 (0.05)
(115)
  PsA csDMARD- IR† 2.20 (0.04)
(107)
2.12 (0.05)
(104)
2.10 (0.03)
(105)
−0.28 (0.05)
(101)**
−0.27 (0.05)
(103)**
−0.11 (0.05)
(102)
  PsA TNFi- IR† 2.24 (0.04)
(130)
2.27 (0.04)
(132)
2.21 (0.04)
(131)
−0.32 (0.04)
(124)**
−0.29 (0.04)
(120)**
−0.12 (0.04)
(117)
  AS NSAID- IR 2.19 (0.06)
(52)
2.31 (0.08)
(52)
2.24 (0.06)
(51)
−0.30 (0.07)
(52)
−0.43 (0.7)
(52)*
−0.22 (0.07)
(51)
Significance is given as unadjusted p values, compared with placebo: *p≤0.05, **p<0.01, ***p<0.001.
For RA and PsA populations, the analysis used a repeated- measures model with fixed effects for treatment, visit, treatment- by- visit interaction, 
geographic location, study (if more than one) and baseline value. A common unstructured covariance matrix was used, without imputation for 
missing values. Data from the two placebo- to- tofacitinib sequences were pooled. For the AS population, an analysis of covariance model was used, 
which included fixed effects of treatment and baseline value. Missing values were imputed by last observation carried forward.
*LS mean change from baseline was assessed at week 12 only in the AS NSAID- IR analysis population.
†PAAP, SF- 36v2 BP domain and EQ- 5D PD dimension have been reported previously for PsA.27 28
‡SF- 36v2 BP is the norm- based BP domain score (theoretical range, 19.23–60.88; higher score=less pain).
§EQ- 5D PD: range 1 (no pain or discomfort) to 3 (extreme pain or discomfort).
¶PAAP measured using a VAS (0–100 mm; higher score=worse arthritis pain).
AS, ankylosing spondylitis; BID, twice daily; BP, Bodily Pain; csDMARD, conventional synthetic disease- modifying antirheumatic drug; EQ- 5D, 
EuroQol Five Dimensions questionnaire; IR, inadequate response; LS, least squares; N, number of patients evaluable at month 3 in the RA and PsA 
populations and number of patients randomised and treated in the AS population; NSAID, non- steroidal anti- inflammatory drug; PAAP, Patient’s 
Assessment of Arthritis Pain; PD, Pain/Discomfort; PsA, psoriatic arthritis; RA, rheumatoid arthriti; SE, standard error; SF- 36v2, Short- Form Health 
Survey 36 version 2; TNFi, tumour necrosis factor inhibitor; VAS, visual analogue scale.
mm was maintained through month 6 (online supple-
mentary figure 2).
short-Form Health survey 36 version 2
In the RA and PsA csDMARD- IR and TNFi- IR popula-
tions, improvements in mean SF- 36v2 Q7 score (bodily 
pain during the past week; lower score indicated less 
pain; online supplementary figure 3) and LS mean 
change from baseline in SF- 36v2 BP domain score 
(higher score indicated less pain; figure 2) were reported 
at the earliest available time point (week 2, RA TNFi- IR 
population; month 1, RA and PsA csDMARD- IR, and PsA 
TNFi- IR populations). Improvements in LS mean change 
from baseline in SF- 36v2 BP domain for tofacitinib 5 
and 10 mg BID treatment groups were significant at all 
time points compared with placebo (all p≤0.05; figure 2; 
table 2). In the tofacitinib 5 and 10 mg BID treatment 
groups, these improvements were maintained through 
month 6 (figure 2; online supplementary figure 3).
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Table 3 Percentage (SE) of patients reporting ≥20 mm improvements from baseline in PAAP at month 3*
Analysis population
Tofacitinib
5 mg BID
Tofacitinib
10 mg BID Placebo
RA csDMARD- IR, % (SE) 53.43 (1.79)*** 57.03 (1.78)*** 27.69 (2.27)
RA TNFi- IR, % (SE) 57.02 (4.64)*** 49.58 (4.58)** 30.43 (4.29)
PsA csDMARD- IR, % (SE) 50.49 (4.93)*** 54.37 (4.91)*** 27.45 (4.42)
PsA TNFi- IR, % (SE) 52.42 (4.48)*** 51.26 (4.58)*** 26.50 (4.08)
Significance is given as unadjusted p values, compared with placebo: **p<0.01, ***p<0.001. Missing values were not imputed. At month 
3, the number of patients evaluable (FAS, N) was: RA csDMARD- IR, n=1938 (tofacitinib 5 mg BID, n=773; tofacitinib 10 mg BID, n=775; 
placebo, n=390); RA TNFi- IR, n=348 (tofacitinib 5 mg BID, n=114; tofacitinib 10 mg BID, n=119; placebo, n=115); PsA csDMARD- IR, n=308 
(tofacitinib 5 mg BID, n=103; tofacitinib 10 mg BID, n=103; placebo, n=102); PsA TNFi- IR, n=360 (tofacitinib 5 mg BID, n=124; tofacitinib 10 
mg BID, n=119; placebo, n=117).
*PAAP measured using a VAS (0–100 mm; higher score=worse arthritis pain).
BID, twice daily; csDMARD, conventional synthetic disease- modifying antirheumatic drug; FAS, full analysis set; IR, inadequate response; 
PAAP, Patient's Assessment of Arthritis Pain; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SE, standard error; TNFi, tumour necrosis 
factor inhibitor; VAS, visual analogue scale.
In the AS NSAID- IR analysis population, SF- 36v2 Q7 
(online supplementary figure 3), improvements were 
observed in patients treated with tofacitinib 5 mg or 10 
mg BID compared with placebo at week 12 (the only 
post- baseline assessment). At week 12, LS mean change 
from baseline in SF- 36v2 BP domain score was signifi-
cantly greater with either dose of tofacitinib compared 
with placebo (both p<0.01; figure 2; table 2).
euroQol 5 dimensions questionnaire Pain/discomfort 
dimension
At month 3 (week 12 in the AS NSAID- IR analysis popu-
lation), the LS mean changes in EQ- 5D PD dimension 
scores were significant across both treatment groups 
and all analysis populations, compared with placebo 
(p≤0.05), with the exception of tofacitinib 5 mg BID in 
the AS NSAID- IR analysis population (p>0.05; table 2; 
online supplementary figure 4). These improvements 
in tofacitinib- treated patients were broadly maintained 
through month 6 (online supplementary figure 4).
Bath ankylosing spondylitis disease activity Index
In the PsA (only in patients who had spondylitis, as deter-
mined by the site investigator at screening, and baseline 
BASDAI total score >0) and AS populations, BASDAI 
Q2 (neck, back or hip pain) and Q3 (peripheral pain/
swelling) scores were improved in both tofacitinib treat-
ment groups and placebo compared with baseline, at 
month 3 and week 12, respectively (online supplemen-
tary figure 5). Improvements were numerically greater for 
patients receiving tofacitinib 5 or 10 mg BID compared 
with placebo. In PsA, improvements in these scores were 
generally maintained through month 6.
ankylosing spondylitis Quality of life questionnaire
In the AS NSAID- IR analysis population, the percentages 
of patients who answered ‘yes’ to ASQoL Q9 or Q14 at 
week 12 were lower compared with baseline values in 
all treatment groups (figure 3). At week 12, the reduc-
tions from baseline in the percentages of patients who 
answered ‘yes’ to Q9 or Q14 were numerically greater in 
patients treated with tofacitinib 5 mg or 10 mg BID than 
those treated with placebo.
dIsCussIOn
The objective of this post- hoc analysis was to further 
evaluate the efficacy of tofacitinib in reducing pain in 
patients with RA, PsA and AS treated in RCTs. While the 
effect of tofacitinib on pain has previously been reported 
in RA,22–26 PsA27 28 and AS,29 this analysis has consid-
ered relevant, pain- specific questions from multidimen-
sional assessments, in addition to the unidimensional 
PAAP- VAS, across disease states and patient populations. 
This analysis has also evaluated all data in the context 
of three inflammatory RMDs and in patients exhibiting 
inadequate responses to previous therapies. Overall, 
patients in all populations treated with tofacitinib 5 mg 
or 10 mg BID showed improvements in all pain assess-
ments, compared with placebo at month 3/week 12. As 
demonstrated in the ORAL Standard and OPAL Broaden 
studies, improvements in outcomes (including pain) 
were numerically similar between tofacitinib and active 
comparator (adalimumab) in the RA24 36 and PsA27 38 
populations—these improvements were maintained in 
most outcomes through month 6. In the AS population, 
these improvements in patients receiving tofacitinib 5 mg 
or 10 mg BID also included the greater reduction from 
baseline in the percentages of patients answering ‘yes’ to 
ASQoL Q9 and Q14.
The experience of pain may be different between 
patients with RA, PsA or AS, due to the distinctive pheno-
types and clinical pattern of presentation. For example, 
in PsA, the presence and severity of both skin and joint 
disease may change patients’ interpretation of pain 
relative to the potentially more joint- specific pain expe-
rienced by patients with RA. Despite this potential differ-
ence in pain experience, tofacitinib, regardless of dose, 
was associated with improvements across different aspects 
of pain across different disease types. Improvements were 
observed in general bodily pain (PAAP, SF- 36v2 Q7 and 
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Figure 2 LS mean (SE) change from baseline in SF- 36v2 BP domain scores (norm- based BP domain score (higher score=less 
pain)) in (A) RA csDMARD- IR, (B) RA TNFi- IR, (C) PsA csDMARD- IR, (D) PsA TNFi- IR and (E) AS NSAID- IR analysis populations 
(FAS). Significance is given as unadjusted p values, compared with placebo: *p≤0.05, **p<0.01, ***p<0.001. For RA and PsA 
populations, LS mean changes from baseline in SF- 36v2 BP domain were analysed using a repeated- measures model with 
fixed effects for treatment group, visit, interaction of the treatment group by visit, geographic location, study (if more than 
one) and baseline value. The model used a common unstructured variance–covariance matrix, without imputation for missing 
data. Within this, two models were used: (1) up to month 3, the two placebo- to- tofacitinib sequences were combined into a 
single placebo group (pooled placebo group); (2) after month 3 (including all post- baseline data up to month 6), the placebo- 
to- tofacitinib sequences were kept separate. For the AS population, treatment comparisons between tofacitinib (5 mg or 10 
mg BID) and placebo at week 12 were made using an analysis of the covariance model, with fixed effects for treatment and 
baseline value; missing values were imputed by last observation carried forward. AS, ankylosing spondylitis; BID, twice daily; 
BP, Bodily Pain; csDMARD, conventional synthetic disease- modifying antirheumatic drug; FAS, full analysis set; IR, inadequate 
response; LS, least squares; NSAID, non- steroidal anti- inflammatory drug; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SE, 
standard error; SF- 36v2, Short- Form Health Survey 36 version 2; TNFi, tumour necrosis factor inhibitor.
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Figure 3 Percentages (SE) of patients from AS NSAID- IR 
population answering ‘yes’ to (A) ASQoL Q9 and (B) ASQoL 
Q14. ASQoL Q9: ‘I have unbearable pain’; ASQoL Q14: ‘The 
pain is always there’. Missing values were not imputed. AS, 
ankylosing spondylitis; ASQoL Q9/14, Ankylosing Spondylitis 
Quality of Life questionnaire Question 9/14; BID, twice 
daily; IR, inadequate response; NSAID, non-steroidal anti- 
inflammatory drug; SE, standard error.
BP domain, ASQoL Q9 and Q14, EQ- 5D PD dimension), 
and in disease- specific neck, back and hip pain (BASDAI 
Q2).
Improvements were observed at the earliest measured 
time point and were similar across patients with an inad-
equate response to csDMARDs (RA and PsA), TNFi (RA 
and PsA) or NSAIDs (AS). This implies that tofacitinib effi-
cacy in relieving pain has a rapid onset, and that efficacy 
may be similar between patients in more and less refrac-
tory populations. In patients with RA, analysis of time- 
to- event data for pain from ORAL Solo (NCT00814307; 
a phase III study comparing tofacitinib 5 mg and 10 mg 
BID monotherapy vs placebo), using an interactive voice- 
response system daily diary, demonstrated differentiation 
from baseline pain as early as 3 days after treatment initi-
ation with tofacitinib.23 Furthermore, in the RA and PsA 
populations reported here, the proportions of patients 
reporting a ≥20 mm improvement were significantly 
higher for patients treated with tofacitinib compared 
with placebo. These results demonstrate that both tofac-
itinib doses (5 mg and 10 mg BID) are efficacious in the 
reduction of pain in many patients, regardless of inade-
quate responses to previous therapies.
The results of the current study appear consistent with 
previous results of bDMARD interventions in patients 
with RA, PsA or AS, with TNFi therapy shown to improve 
patient- reported pain in patients with RA (with an inad-
equate response to csDMARDs),17 PsA18–20 or AS.21 In 
patients with RA, other therapies such as abatacept, anak-
inra and the interleukin-6 inhibitor tocilizumab have 
also improved patient- reported pain.17 Furthermore, 
the magnitude of improvement in pain (as measured by 
VAS) with bDMARDs in RA and PsA appeared to show 
general agreement with the improvements in pain seen 
in patients who received tofacitinib, at similar time points 
(month 6/week 24).
One limitation of this post- hoc analysis is the diffi-
culty in the measurement of pain, a multifactorial 
construct that incorporates both inflammatory and non- 
inflammatory concepts, with current pain measurements 
not definitively attributing pain to either cause. Specific 
to the AS population, it remains a challenge to confirm 
inflammatory back pain, as this is assessed solely based 
on patient input. Further factors limiting the comparison 
and interpretation of these results included the lack of 
confirmation of axial spondyloarthropathy in patients 
with PsA (determined by site investigator at screening 
rather than by imaging), the small AS population and 
differing time points. Additionally, the specific questions 
in the SF- 36v2 (Q7), BASDAI (Q2 and Q3) and ASQoL 
(Q9 and Q14) analysed here were not developed to be 
presented as individual items, but rather to contribute to 
the total or domain- level scores and provide additional 
insight about which items are affecting those scores.15 16 42 
Different time points used across study populations also 
limit the comparison and interpretation of the results. 
Finally, in this manuscript, we focused on the statistical 
significance of improvements in patient- reported pain 
within each disease state, rather than assessing similar-
ities between levels of improvement across diseases. 
The varying designs of the different studies included in 
the analysis meant that a more formal meta- analysis to 
compare responses across diseases was not feasible or 
practical.
In summary, tofacitinib was associated with early and 
sustained improvements in pain, assessed using a range 
of measures, in patients with inflammatory RMDs. 
Improvements appeared consistent, irrespective of tofac-
itinib dose or prior inadequate response to csDMARD, 
TNFi (RA or PsA), or NSAID (AS) treatment. Further 
studies are needed to understand the mechanisms of 
pain in rheumatic diseases, how they differ between these 
diseases and how best to treat pain.
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